Sign in
XLO Stock Price, Chart, Stats & News
Xilio Therapeutics, Inc.
Save
59.77M
Market cap
–
Current P/E
–
Forward P/E
XLO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 96.48% |
Operating margin | -95.92% |
Pretax margin | -80.05% |
Net margin | -80.05% |
Effective tax rate | – |
ROA | -22.65% |
ROE | -311.80% |
D/E | 0.20x |
Interest coverage ratio | – |
XLO valuation
P/E | – |
P/S | 1.10x |
P/B | 19.72x |
P/CF | -139.32x |
P/FCF | -8.73x |
P/OCF | -139.32x |
PEG | -0.59x |
EV multiple | -4.26x |
About
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate).
Similar securities
Based on sector and market capitalization
Report issue